Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Approved for China Launch of PD-L1 for Urothelial Cancer

publication date: Apr 13, 2020

Beijing's BeiGene reported tislelizumab, its PD-1 antibody, was approved to treat urothelial cancer, the drug's second China-approved indication and first solid tumor indication. In December 2019, tislelizumab was approved for classical Hodgkin's lymphoma. In urothelial cancer, tislelizumab is approved for locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed following chemotherapy. BeiGene says tislelizumab is currently being tested in 15 registration-enabling clinical trials, including 11 Phase III trials and four pivotal Phase II trials. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.